We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSPR icon
126
InspireMD
NSPR
$30.9M
– –
0
– –
CLRB icon
127
Cellectar Biosciences
CLRB
$20M
$1.92K 0.06%
21
-3
-13% -$231K
ENDP
128
CALL
DELISTED
Endo International plc
ENDP
$1.82K 0.06%
+253
New +$17.3K
SLXP
129
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.82K 0.06%
158
-42
-21% -$5.09K
NWBO
130
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$1.82K 0.06%
3,394
+41
+1% +$210
XOMA
131
DELISTED
Xoma
XOMA
$1.8K 0.06%
25,087
+3,371
+16% +$289K
REGN icon
132
CALL
Regeneron Pharmaceuticals
REGN
$73.4B
$1.76K 0.06%
43
-227
-84% -$89.3K
WGBS
133
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.76K 0.06%
117,051
+5,731
+5% +$107K
RPRX
134
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$1.74K 0.06%
1,748
+661
+61% +$5.64K
XNTK icon
135
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.98B
$1.66K 0.05%
+178
New +$8.67K
CTIC
136
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.64K 0.05%
696
+522
+300% +$12.1K
HRTX icon
137
Heron Therapeutics
HRTX
$93.3M
$1.64K 0.05%
162,900
-22,100
-12% -$180K
ACGN
138
CALL
DELISTED
Aceragen Inc
ACGN
$1.61K 0.05%
27
+1
+4% +$401
RCPT
139
CALL
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.59K 0.05%
130
+29
+29% +$2.94K
ARIA
140
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.59K 0.05%
2,311
-126
-5% -$788
SRPT icon
141
Sarepta Therapeutics
SRPT
$1.6B
$1.52K 0.05%
105,000
-1,663
-2% -$28.2K
BLRX
142
BioLineRX
BLRX
$12.3M
$1.5K 0.05%
+1,548
New +$1.35M
NPSP
143
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.49K 0.05%
41,670
+27,262
+189% +$814K
CASC
144
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.38K 0.04%
120,750
-68,599
-36% -$745K
SKBI
145
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$1.33K 0.04%
314,367
+25,257
+9% +$109K
FOLD
146
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.33K 0.04%
+1,597
New +$11K
RVNC
147
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.29K 0.04%
76,400
-19,400
-20% -$339K
OPK icon
148
PUT
Opko Health
OPK
$1.12B
$1.28K 0.04%
1,277
-473
-27% -$4.05K
OXGN
149
DELISTED
OXIGENE INC COM
OXGN
$1.26K 0.04%
782,674
-404,924
-34% -$779K
FOMX
150
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.15K 0.04%
163,300
-107,900
-40% -$617K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.